Adding Immunotherapy to Chemotherapy Regimen Improves Surviv

A clinical trial co-led by Mount Sinai researchers is the first to show that using chemotherapy with immunotherapy resulted in improved survival in patients with an advanced type of bladder cancer.

Related Keywords

Matthew Galsky , European Society For Medical Oncology , Bristol Myers Squibb , Tisch Cancer Institute , Ono Pharmaceutical Company Ltd , Tisch Cancer Center At Mount Sinai , Mount Sinai , New England Journal , European Society , Bladder Cancer , Tisch Cancer Center , Ono Pharmaceutical Company , Metastatic Bladder Cancer , Immunotherapy , Chemotherapy ,